1Perou CM.Molecular stratification of triple-negative breast cancers.Oncologist 2010;15 Suppl 5:39-48.
2Perou CM,Sφrlie T,Eisen MB,et al.Molecular portraits of human breast tumours.Nature 2000;406:747-52.
3Sotiriou C,Neo SY,McShane LM,et al.Breast cancer classification and prognosis based on gene expression profiles from a population-based study.Proc Nad Acad Sci U S A 2003;100:10393-8.
4Bidard FC,Conforti R,Boulet T,et al.Does triplenegative phenotype accurately identify basal-like tumour?An immunohistochemical analysis based on 143 ‘triplenegative’ breast cancers.Ann Oncol 2007; 18:1285-6.
5Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.Clin Cancer Res 2004;10:5367-74.
6Cheang MC,Voduc D,Bajdik C,et al.Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.Clin Cancer Res 2008;14:1368-76.
7Bauer KR,Brown M,Cress RD,et al.Descriptive analysis of estrogen receptor (ER)-negative,progesterone receptor (PR)-negative,and HER2-negative invasive breast cancer,the so-called triple-negative phenotype:a populationbased study from the California cancer Registry.Cancer 2007;109:1721-8.
8André F,Zielinski CC.Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.Ann Oncol 2012 ;23 Suppl 6:vi46-51.
9Coughlin SS,Ekwueme DU.Breast cancer as a global health concern.Cancer Epidemiol 2009; 33:315-8.
10Ismail-Khan R,Bui MM.A review of triple-negative breast cancer.Cancer Control 2010; 17:173-6.
